Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan

Chensu Wang, Hanspeter Niederstrasser, Peter M. Douglas, Rueyling Lin, Juan Jaramillo, Yang Li, Nathaniel W. Olswald, Anwu Zhou, Elizabeth A. McMillan, Saurabh Mendiratta, Zhaohui Wang, Tian Zhao, Zhiqaing Lin, Min Luo, Gang Huang, Rolf A. Brekken, Bruce A. Posner, John B. MacMillan, Jinming Gao, Michael A. White

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Drugs that mirror the cellular effects of starvation mimics are considered promising therapeutics for common metabolic disorders, such as obesity, liver steatosis, and for ageing. Starvation, or caloric restriction, is known to activate the transcription factor EB (TFEB), a master regulator of lipid metabolism and lysosomal biogenesis and function. Here, we report a nanotechnology-enabled high-throughput screen to identify small-molecule agonists of TFEB and discover three novel compounds that promote autophagolysosomal activity. The three lead compounds include the clinically approved drug, digoxin; the marine-derived natural product, ikarugamycin; and the synthetic compound, alexidine dihydrochloride, which is known to act on a mitochondrial target. Mode of action studies reveal that these compounds activate TFEB via three distinct Ca2+-dependent mechanisms. Formulation of these compounds in liver-tropic biodegradable, biocompatible nanoparticles confers hepatoprotection against diet-induced steatosis in murine models and extends lifespan of Caenorhabditis elegans. These results support the therapeutic potential of small-molecule TFEB activators for the treatment of metabolic and age-related disorders.

Original languageEnglish (US)
Article number2270
JournalNature Communications
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

mice
Transcription Factors
Molecules
Starvation
liver
Liver
molecules
drugs
lipid metabolism
obesity
disorders
biological evolution
Lead compounds
lead compounds
Tropics
diets
Caloric Restriction
Nanotechnology
Digoxin
regulators

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan. / Wang, Chensu; Niederstrasser, Hanspeter; Douglas, Peter M.; Lin, Rueyling; Jaramillo, Juan; Li, Yang; Olswald, Nathaniel W.; Zhou, Anwu; McMillan, Elizabeth A.; Mendiratta, Saurabh; Wang, Zhaohui; Zhao, Tian; Lin, Zhiqaing; Luo, Min; Huang, Gang; Brekken, Rolf A.; Posner, Bruce A.; MacMillan, John B.; Gao, Jinming; White, Michael A.

In: Nature Communications, Vol. 8, No. 1, 2270, 01.12.2017.

Research output: Contribution to journalArticle

Wang, Chensu ; Niederstrasser, Hanspeter ; Douglas, Peter M. ; Lin, Rueyling ; Jaramillo, Juan ; Li, Yang ; Olswald, Nathaniel W. ; Zhou, Anwu ; McMillan, Elizabeth A. ; Mendiratta, Saurabh ; Wang, Zhaohui ; Zhao, Tian ; Lin, Zhiqaing ; Luo, Min ; Huang, Gang ; Brekken, Rolf A. ; Posner, Bruce A. ; MacMillan, John B. ; Gao, Jinming ; White, Michael A. / Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan. In: Nature Communications. 2017 ; Vol. 8, No. 1.
@article{4c8ee5f3e1ac4a1eafe8994a86300c64,
title = "Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan",
abstract = "Drugs that mirror the cellular effects of starvation mimics are considered promising therapeutics for common metabolic disorders, such as obesity, liver steatosis, and for ageing. Starvation, or caloric restriction, is known to activate the transcription factor EB (TFEB), a master regulator of lipid metabolism and lysosomal biogenesis and function. Here, we report a nanotechnology-enabled high-throughput screen to identify small-molecule agonists of TFEB and discover three novel compounds that promote autophagolysosomal activity. The three lead compounds include the clinically approved drug, digoxin; the marine-derived natural product, ikarugamycin; and the synthetic compound, alexidine dihydrochloride, which is known to act on a mitochondrial target. Mode of action studies reveal that these compounds activate TFEB via three distinct Ca2+-dependent mechanisms. Formulation of these compounds in liver-tropic biodegradable, biocompatible nanoparticles confers hepatoprotection against diet-induced steatosis in murine models and extends lifespan of Caenorhabditis elegans. These results support the therapeutic potential of small-molecule TFEB activators for the treatment of metabolic and age-related disorders.",
author = "Chensu Wang and Hanspeter Niederstrasser and Douglas, {Peter M.} and Rueyling Lin and Juan Jaramillo and Yang Li and Olswald, {Nathaniel W.} and Anwu Zhou and McMillan, {Elizabeth A.} and Saurabh Mendiratta and Zhaohui Wang and Tian Zhao and Zhiqaing Lin and Min Luo and Gang Huang and Brekken, {Rolf A.} and Posner, {Bruce A.} and MacMillan, {John B.} and Jinming Gao and White, {Michael A.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41467-017-02332-3",
language = "English (US)",
volume = "8",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan

AU - Wang, Chensu

AU - Niederstrasser, Hanspeter

AU - Douglas, Peter M.

AU - Lin, Rueyling

AU - Jaramillo, Juan

AU - Li, Yang

AU - Olswald, Nathaniel W.

AU - Zhou, Anwu

AU - McMillan, Elizabeth A.

AU - Mendiratta, Saurabh

AU - Wang, Zhaohui

AU - Zhao, Tian

AU - Lin, Zhiqaing

AU - Luo, Min

AU - Huang, Gang

AU - Brekken, Rolf A.

AU - Posner, Bruce A.

AU - MacMillan, John B.

AU - Gao, Jinming

AU - White, Michael A.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Drugs that mirror the cellular effects of starvation mimics are considered promising therapeutics for common metabolic disorders, such as obesity, liver steatosis, and for ageing. Starvation, or caloric restriction, is known to activate the transcription factor EB (TFEB), a master regulator of lipid metabolism and lysosomal biogenesis and function. Here, we report a nanotechnology-enabled high-throughput screen to identify small-molecule agonists of TFEB and discover three novel compounds that promote autophagolysosomal activity. The three lead compounds include the clinically approved drug, digoxin; the marine-derived natural product, ikarugamycin; and the synthetic compound, alexidine dihydrochloride, which is known to act on a mitochondrial target. Mode of action studies reveal that these compounds activate TFEB via three distinct Ca2+-dependent mechanisms. Formulation of these compounds in liver-tropic biodegradable, biocompatible nanoparticles confers hepatoprotection against diet-induced steatosis in murine models and extends lifespan of Caenorhabditis elegans. These results support the therapeutic potential of small-molecule TFEB activators for the treatment of metabolic and age-related disorders.

AB - Drugs that mirror the cellular effects of starvation mimics are considered promising therapeutics for common metabolic disorders, such as obesity, liver steatosis, and for ageing. Starvation, or caloric restriction, is known to activate the transcription factor EB (TFEB), a master regulator of lipid metabolism and lysosomal biogenesis and function. Here, we report a nanotechnology-enabled high-throughput screen to identify small-molecule agonists of TFEB and discover three novel compounds that promote autophagolysosomal activity. The three lead compounds include the clinically approved drug, digoxin; the marine-derived natural product, ikarugamycin; and the synthetic compound, alexidine dihydrochloride, which is known to act on a mitochondrial target. Mode of action studies reveal that these compounds activate TFEB via three distinct Ca2+-dependent mechanisms. Formulation of these compounds in liver-tropic biodegradable, biocompatible nanoparticles confers hepatoprotection against diet-induced steatosis in murine models and extends lifespan of Caenorhabditis elegans. These results support the therapeutic potential of small-molecule TFEB activators for the treatment of metabolic and age-related disorders.

UR - http://www.scopus.com/inward/record.url?scp=85039417721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039417721&partnerID=8YFLogxK

U2 - 10.1038/s41467-017-02332-3

DO - 10.1038/s41467-017-02332-3

M3 - Article

VL - 8

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 2270

ER -